Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623939 | 0.93 | HSD17B10 (0.42) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL21454476 | 0.93 | HSD17B10 (0.42) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL21454477 | 0.91 | HSD17B10 (0.44) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL24220956 | 0.88 | HSD17B10 (0.47) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL21764427 | 0.88 | HSD17B10 (0.47) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL20202265 | 0.88 | HSD17B10 (0.47) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL10284339 | 0.88 | HSD17B10 (0.47) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL29299636 | 0.87 | SIGMAR1 (0.38) | SIGMAR1HSD17B10SLC6A9NPC1CHRM5 | |
| SCHEMBL9119001 | 0.86 | HSD17B10 (0.48) | SIGMAR1HSD17B10SLC6A9ALDH1A1GAA | |
| SCHEMBL12018111 | 0.86 | HSD17B10 (0.48) | SIGMAR1HSD17B10SLC6A9ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | SIGMAR1 4436/4885HSD17B10 3607/4885SLC6A9 4564/4885 |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | PSMA1, ALB, PSMA2 | SIGMAR1 3315/4885HSD17B10 3053/4885SLC6A9 562/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | SIGMAR1 4436/4885HSD17B10 3607/4885SLC6A9 4564/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | SIGMAR1 4808/4885HSD17B10 3449/4885SLC6A9 4366/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | SIGMAR1 3790/4885HSD17B10 2957/4885SLC6A9 705/4885 |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | PSMA1, ALB, PSMA2 | SIGMAR1 3315/4885HSD17B10 3053/4885SLC6A9 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.